These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24750110)

  • 21. Management of Myeloma Bone Lesions.
    Du JS; Yen CH; Hsu CM; Hsiao HH
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloma bone disease: from biology findings to treatment approaches.
    Terpos E; Ntanasis-Stathopoulos I; Dimopoulos MA
    Blood; 2019 Apr; 133(14):1534-1539. PubMed ID: 30760454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Management of multiple myeloma-related bone disease].
    Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; Małecki K; Skotnicki AB
    Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orthopaedics: Structural support.
    Berglund J
    Nature; 2011 Dec; 480(7377):S56-7. PubMed ID: 22169807
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic options in the management of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
    Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the bone microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Metab; 2010 May; 28(3):244-50. PubMed ID: 20127498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.
    Kleber M; Udi J; Metzke B; Terpos E; Roodmann GD; Morgan G; Dispenzieri A; Einsele H; Wäsch R; Engelhardt M
    Leuk Lymphoma; 2012 Jun; 53(6):1057-61. PubMed ID: 22149167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New agents in the Treatment of Myeloma Bone Disease.
    Ring ES; Lawson MA; Snowden JA; Jolley I; Chantry AD
    Calcif Tissue Int; 2018 Feb; 102(2):196-209. PubMed ID: 29098361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates and bone diseases: past, present and future.
    Heymann D
    Curr Pharm Des; 2010; 16(27):2948-9. PubMed ID: 20722613
    [No Abstract]   [Full Text] [Related]  

  • 31. Tumor-host cell interactions in the bone disease of myeloma.
    Fowler JA; Edwards CM; Croucher PI
    Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of bone lesions in multiple myeloma].
    Hata H; Mitsuya H
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights into the pathophysiology and management of bone disease in multiple myeloma.
    Terpos E; Politou M; Rahemtulla A
    Br J Haematol; 2003 Dec; 123(5):758-69. PubMed ID: 14632767
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
    Ural AU; Avcu F
    Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
    [No Abstract]   [Full Text] [Related]  

  • 35. Bone Disease in Myeloma: The Claws of CRAB.
    Fonseca R; Jain T
    Clin Cancer Res; 2016 Mar; 22(6):1301-3. PubMed ID: 26792259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloma bone disease and treatment options.
    Yeh HS; Berenson JR
    Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloma and Bone Disease.
    Panaroni C; Yee AJ; Raje NS
    Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
    Lund T; Gundesen MT; Juul Vangsted A; Helleberg C; Haukås E; Silkjær T; Asmussen JT; Manuela Teodorescu E; Amdi Jensen B; Schmidt Slørdahl T; Nahi H; Waage A; Abildgaard N; Schjesvold F;
    Blood Cancer J; 2024 Apr; 14(1):65. PubMed ID: 38622134
    [No Abstract]   [Full Text] [Related]  

  • 39. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
    J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current approaches in multiple myeloma and other cancer-related bone diseases].
    Engelhardt M; Kleber M; Udi J; Wäsch R
    Dtsch Med Wochenschr; 2012 May; 137(20):1057-61. PubMed ID: 22549292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.